AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31038012 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 29477094 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of familiar category instances with highlighted function information
Number of subjects: 0
Study 29477094 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to function information
Number of subjects: 0
Study 29477094 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of two perceptually similar category members
Number of subjects: 0
Study 27809848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin treatment
Number of subjects: 463
Study 27809848 — intervention group
Group type: COMPARATOR
Intervention: Conventional anti-diabetic agents
Number of subjects: 463
Study 27809848 — intervention group
Group type: EXPERIMENTAL
Intervention: Good glycemic control (HbA1c <7.0)
Number of subjects: 463
Study 27809848 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor glycemic control (HbA1c ≥7.0)
Number of subjects: 463
Study 24508847 — intervention group
Group type: COMPARATOR
Intervention: Cardiac MR
Number of subjects: 898
Study 24508847 — intervention group
Group type: COMPARATOR
Intervention: SPECT-MIBI
Number of subjects: 898
Study 24508847 — intervention group
Group type: COMPARATOR
Intervention: ECHO
Number of subjects: 898
Study 22082673 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 124
Study 22082673 — intervention group
Group type: COMPARATOR
Intervention: Surgical ablation (SA)
Number of subjects: 124
Study 20557816 — intervention group
Group type: EXPERIMENTAL
Intervention: PLDLA metatarsophalangeal joint interposition arthroplasty
Number of subjects: 35
Study 20557816 — intervention group
Group type: COMPARATOR
Intervention: Conventional metatarsal head resection
Number of subjects: 35
Study 18726111 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual leg plantar flexion training (4 x 4 min intervals at 80% of maximal work rate, three times per week for 8 weeks)
Number of subjects: 27
Study 18726111 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual leg plantar flexion training
Number of subjects: 27
Study 18726111 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 15190858 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention based on a model of practice change.
Number of subjects: 79
Study 15190858 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding the four key elements of practice change.
Number of subjects: 79
Study 11106050 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Discharge
Number of subjects: 308
Study 11106050 — intervention group
Group type: COMPARATOR
Intervention: Routine Discharge
Number of subjects: 308
Study 9217377 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500000 KIU of aprotinin (group A)
Number of subjects: 200
Study 9217377 — intervention group
Group type: EXPERIMENTAL
Intervention: 300000 KIU of aprotinin (group B)
Number of subjects: 200
Study 9217377 — intervention group
Group type: COMPARATOR
Intervention: No aprotinin (group C)
Number of subjects: 200
Study 8376274 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg)
Number of subjects: 10
Study 8376274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10276475 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 310
Study 31159796 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-being therapy (WBT) for 5 weeks, n=39
Number of subjects: 101
Study 31159796 — intervention group
Group type: COMPARATOR
Intervention: Placebo control condition (CC) for 5 weeks, n=48
Number of subjects: 101
Study 29247098 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention inspired by Stuifbergen's model; conducted during three nurse-led sessions.
Number of subjects: 71
Study 25881796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (single dose)
Number of subjects: 0
Study 25881796 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 24680087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) - intravenous 1 g bolus, 1 g infusion/8 h
Number of subjects: 24
Study 24680087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22001815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% fluorescein with 0.5% proxymetacaine hydrochloride dye
Number of subjects: 15
Study 22001815 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with 2 ml of balanced saline solution
Number of subjects: 15
Study 19155004 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus cyclic medroxyprogesterone acetate (MPA) 5 mg twice a day
Number of subjects: 40
Study 19155004 — intervention group
Group type: COMPARATOR
Intervention: Metformin 850 mg twice a day
Number of subjects: 40
Study 17519068 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost/timolol fixed combination (BTFC)
Number of subjects: 36
Study 17519068 — intervention group
Group type: COMPARATOR
Intervention: latanoprost/timolol fixed combination (LTFC)
Number of subjects: 36
Study 17519068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 36
Study 15551160 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimoxazole plus doxycycline (CD group)
Number of subjects: 280
Study 15551160 — intervention group
Group type: COMPARATOR
Intervention: co‐trimoxazole plus rifampin (CR group)
Number of subjects: 280
Study 11032226 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises
Number of subjects: 60
Study 11032226 — intervention group
Group type: COMPARATOR
Intervention: Open kinetic chain exercises
Number of subjects: 60
Study 9094726 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of nebulized ipratropium added to three albuterol nebulizations administered over 1 hour
Number of subjects: 120
Study 9094726 — intervention group
Group type: COMPARATOR
Intervention: 0 doses of nebulized ipratropium added to three albuterol nebulizations administered over 1 hour
Number of subjects: 120
Study 7682029 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4-12 mg
Number of subjects: 37
Study 7682029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2823869 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre isolates (various water-soluble chemical isolates)
Number of subjects: 6
Study 2823869 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 6
Study 2823869 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre isolates
Number of subjects: 6
Study 30425014 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy (thermomechanical stimulation) during injection
Number of subjects: 497
Study 30425014 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Buzzy)
Number of subjects: 497
Study 29797235 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 250 μg once daily for 4 weeks
Number of subjects: 1238
Study 29797235 — intervention group
Group type: COMPARATOR
Intervention: Roflumilast 500 μg every other day
Number of subjects: 1238
Study 29797235 — intervention group
Group type: COMPARATOR
Intervention: Roflumilast 500 μg once daily
Number of subjects: 1238
Study 27634091 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue manipulation (CTM) twice per week for 6 weeks
Number of subjects: 20
Study 27634091 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CG)
Number of subjects: 20
Study 27634091 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue manipulation (CTM)
Number of subjects: 20
Study 25714532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-flared 45-degree Kelman tip
Number of subjects: 150
Study 25714532 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed mini-flared 30-degree Kelman tip
Number of subjects: 150
Study 25714532 — intervention group
Group type: COMPARATOR
Intervention: Sidewinder 30-degree Kelman tip
Number of subjects: 150
Study 23875818 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic single-dose antibiotic administered preoperatively
Number of subjects: 953
Study 23875818 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic single-dose antibiotic administered at cord clamping
Number of subjects: 953
Study 20921085 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day) 3 weeks before surgery
Number of subjects: 90
Study 20921085 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (10 mg/kg, single shot)
Number of subjects: 90
Study 20921085 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 18263802 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) infusion (50 mg/kg body mass)
Number of subjects: 18
Study 18263802 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study 16698215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 182
Study 16698215 — intervention group
Group type: EXPERIMENTAL
Intervention: Candiduria
Number of subjects: 182
Study 14620117 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX microtextured implant surfaces
Number of subjects: 9
Study 14620117 — intervention group
Group type: COMPARATOR
Intervention: Machined implant surfaces
Number of subjects: 9
Study 10928438 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% caudally (0.5 mL kg(‐1))
Number of subjects: 60
Study 10928438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% caudally (0.5 mL kg(‐1)) + Clonidine (1 microg kg(‐1))
Number of subjects: 60
Study 10928438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% caudally (0.5 mL kg(‐1)) + Sufentanil (0.5 microg kg(‐1))
Number of subjects: 60
Study 10928438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% caudally (0.5 mL kg(‐1)) + Clonidine (0.5 microg kg(‐1)) + Sufentanil (0.25 microg kg(‐1))
Number of subjects: 60
Study 8909667 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aerosolized prostacyclin 50 ng/kg/min
Number of subjects: 5
Study 8909667 — intervention group
Group type: COMPARATOR
Intervention: Nitric oxide 10 ppm
Number of subjects: 5
Study 1565753 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aware of the menstrual cycle focus of the study (asymptomatic group)
Number of subjects: 65
Study 1565753 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with severe symptoms (LLPDD group)
Number of subjects: 65
Study 1565753 — intervention group
Group type: COMPARATOR
Intervention: Women unaware of the menstrual cycle focus of the study (asymptomatic group)
Number of subjects: 65
Study 31907755 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander intervention (Green Dot presentations and intensive bystander training)
Number of subjects: 74836
Study 31907755 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander intervention
Number of subjects: 74836
Study 31907755 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74836
Study 30473179 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP levels (very high)
Number of subjects: 867
Study 30473179 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal CRP at weeks 2, 4, and 8
Number of subjects: 867
Study 30473179 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP levels
Number of subjects: 867
Study 30473179 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and post-baseline CRP levels
Number of subjects: 867
Study 28841847 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who are activated (e.g., ask questions, express opinions, ask for clarification)
Number of subjects: 91
Study 28841847 — intervention group
Group type: COMPARATOR
Intervention: Patients who are typical (not activated)
Number of subjects: 91
Study 25134036 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) intervention
Number of subjects: 480
Study 24460069 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily walking intervention (10,000 steps per day and a weekly supervised group walk) for 10 weeks
Number of subjects: 0
Study 24460069 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily walking intervention
Number of subjects: 0
Study 24460069 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21842965 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability discounting
Number of subjects: 226
Study 21842965 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay discounting
Number of subjects: 226
Study 19709327 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous leaf extracts of Syzygium cumini (ASC) at 60-1000 microg/mL
Number of subjects: 0
Study 19709327 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous leaf extracts of Syzygium cumini (ASC)
Number of subjects: 0
Study 19709327 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemic serum
Number of subjects: 0
Study 17490981 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye-pasta diet
Number of subjects: 47
Study 17490981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-wheat-potato diet
Number of subjects: 47
Study 15760312 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 40
Study 15760312 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management (vaginal misoprostol)
Number of subjects: 40
Study 15760312 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 40
Study 15760312 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 40
Study 12377799 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micro g LT
Number of subjects: 42
Study 12377799 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 micro g LT
Number of subjects: 42
Study 12377799 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 micro g LT
Number of subjects: 42
Study 12377799 — intervention group
Group type: EXPERIMENTAL
Intervention: no LT
Number of subjects: 42
Study 12377799 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterically delivered urease
Number of subjects: 42
Study 10199429 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens, 1.25 mg/d for 21 days
Number of subjects: 46
Study 7754476 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatments (various drugs prescribed by homeopathic physicians)
Number of subjects: 237
Study 2271192 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour nil per os (NPO) group (19 infants kept NPO for 3 hours following ingestion of up to 4 ounces of 5% dextrose in water)
Number of subjects: 44
Study 2271192 — intervention group
Group type: COMPARATOR
Intervention: 10-hour NPO group (25 infants who remained NPO an average of 10 hours prior to surgery)
Number of subjects: 44
Study 2271192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dye-dilution technique
Number of subjects: 44
Study 2271192 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration technique
Number of subjects: 44
Study 2271192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 7361691 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholemeal bread
Number of subjects: 0
Study 7361691 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread enriched with zinc chloride
Number of subjects: 0
Study 7361691 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholemeal bread with added calcium (milk products)
Number of subjects: 0
Study 7361691 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals containing milk, cheese, beef, and egg with wholemeal bread
Number of subjects: 0
Study 31805422 — intervention group
Group type: COMPARATOR
Intervention: Stepped-wedge cluster randomized controlled trial design
Number of subjects: 0
Study 31805422 — intervention group
Group type: COMPARATOR
Intervention: Typical SW design
Number of subjects: 0
Study 31805422 — intervention group
Group type: COMPARATOR
Intervention: SW design with multiple clusters crossing over per period
Number of subjects: 0
Study 31805422 — intervention group
Group type: COMPARATOR
Intervention: Hierarchical randomization
Number of subjects: 0
Study 31805422 — intervention group
Group type: COMPARATOR
Intervention: Nested substudies
Number of subjects: 0
Study 31805422 — intervention group
Group type: COMPARATOR
Intervention: Hybrid SW design
Number of subjects: 0
Study 31805422 — intervention group
Group type: COMPARATOR
Intervention: Incomplete SW design variations
Number of subjects: 0
Study 31366999 — intervention group
Group type: EXPERIMENTAL
Intervention: Home weight control programme
Number of subjects: 409
Study 31366999 — intervention group
Group type: EXPERIMENTAL
Intervention: Community weight control programme
Number of subjects: 409
Study 31366999 — intervention group
Group type: COMPARATOR
Intervention: Standard written advice (control)
Number of subjects: 409
Study 30303664 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 123
Study 30303664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalargin therapy (2 mg/day for 10 days, 3 courses during 3 months)
Number of subjects: 123
Study 25566706 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin (Group A; n = 24)
Number of subjects: 50
Study 25566706 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Group B; n = 26)
Number of subjects: 50
Study 23418000 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 14
Study 19514183 — intervention group
Group type: EXPERIMENTAL
Intervention: needle‐rolling therapy
Number of subjects: 180
Study 19514183 — intervention group
Group type: COMPARATOR
Intervention: clonopin (control)
Number of subjects: 180
Study 16772810 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/d (increased to mean 10.55 mg/d)
Number of subjects: 51
Study 16772810 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine 20 mg/d (fixed dose)
Number of subjects: 51
Study 15618849 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy during colonoscopy
Number of subjects: 118
Study 15618849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 118
Study 11819728 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (Group A)
Number of subjects: 147
Study 11819728 — intervention group
Group type: COMPARATOR
Intervention: Hepatic artery ligation (HAL) and/or hepatic artery infusion (HAI) (Group B)
Number of subjects: 147
Study 11819728 — intervention group
Group type: COMPARATOR
Intervention: Removal of HCC with PVTT (Group C)
Number of subjects: 147
Study 11819728 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter hepatic arterial chemoembolization (TACE) or HAI and/or portal vein infusion (PVI) after operation (Group D)
Number of subjects: 147
Study 9247243 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (blast type)
Number of subjects: 14
Study 7509784 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Trasylol (Hammersmith dosage: 6 x 10(6) KIU)
Number of subjects: 120
Study 7509784 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose Trasylol (half of Hammersmith dosage)
Number of subjects: 120
Study 7509784 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Trasylol
Number of subjects: 120
Study 7509784 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose Trasylol
Number of subjects: 120
Study 7509784 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Trasylol and Low Dose Trasylol
Number of subjects: 120
Study 2959236 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (average dosage 265 mg/d, range 150-300 mg)
Number of subjects: 25
Study 2959236 — intervention group
Group type: COMPARATOR
Intervention: Minoxidil (average dosage 19.6 mg/d, range 7.5-30 mg)
Number of subjects: 25
Study 31948461 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (n = 40)
Number of subjects: 130
Study 31948461 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (n = 48)
Number of subjects: 130
Study 29866645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0
Study 27501153 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ supplementation
Number of subjects: 0
Study 27501153 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Number of subjects: 0
Study 25046515 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline-caffeine beverage
Number of subjects: 60
Study 25046515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23533254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine (0-100 µg)
Number of subjects: 11
Study 23533254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine (0-8.8 mg)
Number of subjects: 11
Study 20592725 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (two 510 mg doses administered 24 h apart)
Number of subjects: 58
Study 20592725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 17483103 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month lifestyle program focusing on weight loss, diet, and exercise
Number of subjects: 241
Study 16841666 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and multi-glycosides of tripterygii (MT)
Number of subjects: 0
Study 16841666 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 0
Study 11834754 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10493671 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DMA*0104 in patients with SLE
Number of subjects: 108
Study 10493671 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 108
Study 8545138 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (custom-made capsules)
Number of subjects: 37
Study 8545138 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (suppositories)
Number of subjects: 37
Study 8545138 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone (control)
Number of subjects: 37
Study 1902052 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (ECA) 325 mg
Number of subjects: 15
Study 1902052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6126475 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 40